ArticleJournal of food and drug analysis2023
Development of a lateral flow immunoassays-based method for the screening of ractopamine in foods and evaluation of the optimal strategy in combination of screening and confirmatory tests.
Article in Journal of food and drug analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ractopamine has been authorized as a feed additive and permitted in animal husbandry. With the establishment of the regulation to limit the concentration of ractopamine, a rapid screening method for ractopamine is urgently needed. Additionally, how to combine the screening and confirmatory tests of ractopamine is also critical to maximizing the efficiency of testing. Here, we developed a lateral flow immunoassays-based method for the screening of ractopamine in foods and proposed a cost-benefit analysis approach to optimize cost allocation between screening and confirmatory tests. After verifying the analytical and clinical performances of the screening method, a mathematical model was established to calculate the screening and confirmatory test results with various parameter settings, such as cost allocation, false-negative tolerance, and total budget size. The developed immunoassay-based screening test could successfully distinguish gravy samples with ractopamine levels over and lower than maximum residue limits (MRL). The area under curve (AUC) value of receiver operating characteristic (ROC) curve is 0.99. For the cost-benefit analysis, mathematical simulation indicated that when the samples are allocated to screening and confirmatory tests at the optimized cost allocation, the number of confirmed positive samples can increase by 26 times compared to the scenarios entirely relying on confirmatory testing. While conventional wisdom considers that screening should be carried out at low false-negative rates, such as 0.1%, our results indicated that the cutoff value of a screening test with a 20% false-negative rate at MRL could capture the maximum number of confirmed positive samples at a limited budget. Our work indicated that the participation of the screening method in ractopamine analysis and optimized cost allocation between screening and confirmatory tests could enhance the efficiency in detecting the positive samples, which provides a rational basis for decision-making in food safety enforcement for public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.